Cost–Effectiveness of Rivaroxaban Versus Heparins for Prevention of Venous Thromboembolism After Total Hip or Knee Surgery in Sweden

Lars Ryttberg; Alex Diamantopoulos; Fiona Forster; Michael Lees; Anina Fraschke; Ingela Björholt


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(5):601-615. 

In This Article

Utility Data

The analysis incorporates utility values from a combination of studies in the literature. The baseline health state for patients without complications after THR or TKR was derived from a Finnish study where patients who were due to undergo THR or TKR had a utility value of 0.805 (mean age of 63 years) and 0.807 (mean age of 69 years), respectively. A total of 12 months after operation, the utility value was 0.858 for THR patients and 0.841 for TKR patients.[20] These values are applied for the variables no event and asymptomatic event, and are also used to weight the values for each of the complications occurring, thereby also accounting for the age of this patient group. The duration of disease was estimated as 3 months for symptomatic DVT and 6 months for PE (Table 2).

For patients who experienced more than one event in the same cycle (year), the lowest utility value was applied in that cycle.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.